CLINICAL TRIALS PROFILE FOR DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00293644 ↗ | Pre-emptive Treatment of Severe Nausea and Vomiting of Pregnancy | Completed | Duchesnay Inc. | Phase 3 | 2006-02-01 | The purpose of this study is to determine whether pre-emptive use of a delayed release combination of pyridoxine hydrochloride and doxylamine succinate (Diclectin®), before eruption of symptoms of Nausea and vomiting of pregnancy and hyperemesis gravidarum, will reduce the incidence of severe forms of this syndrome/HG. |
| NCT00293644 ↗ | Pre-emptive Treatment of Severe Nausea and Vomiting of Pregnancy | Completed | The Hospital for Sick Children | Phase 3 | 2006-02-01 | The purpose of this study is to determine whether pre-emptive use of a delayed release combination of pyridoxine hydrochloride and doxylamine succinate (Diclectin®), before eruption of symptoms of Nausea and vomiting of pregnancy and hyperemesis gravidarum, will reduce the incidence of severe forms of this syndrome/HG. |
| NCT00614445 ↗ | The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy | Completed | Premier Research Group plc | Phase 3 | 2008-01-01 | The purpose of this study is to determine whether Diclectin® (doxylamine succinate USP 10 mg and pyridoxine HCl 10 mg) is more effective at controlling the nausea and vomiting of pregnancy than a placebo. |
| NCT00614445 ↗ | The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy | Completed | Duchesnay Inc. | Phase 3 | 2008-01-01 | The purpose of this study is to determine whether Diclectin® (doxylamine succinate USP 10 mg and pyridoxine HCl 10 mg) is more effective at controlling the nausea and vomiting of pregnancy than a placebo. |
| NCT03905564 ↗ | A Study to Investigate Differences in the Extent and Rate of Absorption of Doxylamine/Pyridoxine From 2 Different Products Under Fasting Conditions | Withdrawn | Grünenthal, S.A. | Phase 1 | 2019-06-01 | The purpose of the study is to investigate any difference in the extent and rate of absorption of doxylamine between the test (investigational medicinal product [IMP]) and reference products that could impact the bioavailability of the medication when administered under fasting conditions. |
| NCT03905564 ↗ | A Study to Investigate Differences in the Extent and Rate of Absorption of Doxylamine/Pyridoxine From 2 Different Products Under Fasting Conditions | Withdrawn | Grünenthal GmbH | Phase 1 | 2019-06-01 | The purpose of the study is to investigate any difference in the extent and rate of absorption of doxylamine between the test (investigational medicinal product [IMP]) and reference products that could impact the bioavailability of the medication when administered under fasting conditions. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE
Condition Name
Clinical Trial Locations for DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE
Sponsor Name
